Vita 34 AG
V3V
ISIN DE000A0BL849 / Valor 2333201
Vita 34 AG
UMushroom community rating:
About company
Vita 34 AG is a full-service provider in the field of cell banking and stem cell banking, offering services from removal and processing to preservation and delivery. With approximately 100 employees, the company specializes in storing stem cells for medical purposes, providing a crucial service for individuals looking to safeguard their health and well-being. Vita 34 AG's expertise in this niche area of healthcare positions them as a key player in the industry, catering to the growing demand for personalized medical solutions.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (08.11.2025):
In the first quarter of 2024, Vita 34 AG reported significant financial improvements marking a strong start to the fiscal year. The company, a leading cell bank in Europe, saw increased revenues, notable growth in invoiced services from its end consumer (B2C) business, and a substantial boost in EBITDA and operating cash flow amidst evolving market dynamics and renewed customer contracts.
Revenue Growth
Revenues for Q1 2024 reached EUR 18.6 million, up 3.6% compared to EUR 17.9 million in Q1 2023, indicating steady growth despite market challenges in acquiring new customers.
B2C and Recurring Revenue
The net amount of invoiced services in the B2C segment increased by 13.6% to EUR 18.0 million, with annually recurring payments rising to EUR 5.7 million from EUR 5.2 million in the prior year, driven by higher demand for contract renewals and a shift toward higher-value product packages.
EBITDA Improvement
EBITDA saw a significant increase, climbing to EUR 1.5 million in Q1 2024 compared to just EUR 0.3 million in Q1 2023, largely due to cost discipline and the reversal of previous special effects.
Operating Cash Flow
Operating cash flow improved markedly to EUR 4.0 million, reflecting cost optimizations in administration, marketing, and sales, alongside a robust performance in the renewals business.
Forward Outlook
The management confirmed its positive outlook for 2024, forecasting total revenues between EUR 81 and 88 million and EBITDA between EUR 6.5 and 8.0 million, underscoring the company's strong financial position as it enters the new fiscal year.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
106 M
Market cap (USD)
90
Daily traded volume (Shares)
4.08 / 4
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
